An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)
NCT02776735
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
102
Enrollment
INDUSTRY
Sponsor class
Conditions
Juvenile Idiopathic Arthritis
Interventions
DRUG:
Sarilumab
Sponsor
Sanofi
Collaborators
[object Object]